According to results of a multiple-dose studies at the 2021 ASH Annual Meeting, treatment with etavopivat, a small molecule activator of erythrocyte pyruvate kinase, improved anemia and decreased intravascular hemolysis in patients with sickle cell disease (SCD) treated for up to 12 weeks. Previous studies demonstrated that etavopivat resulted in decreased levels of 2,3-disphosphoglyceric acid (2,3-DPG) and increased levels of adenosine triphosphate (ATP) in red blood cells (RBCs) of healthy volunteers and patients with SCD. In the present analysis, researchers evaluated the effects of etavopivat in two-week multiple ascending dose ...
Advertisement
Many patients with CLL receive chemoimmunotherapy, which can cause additional issues with the immune system.
A study combined artificial intelligence with electrocardiography to predict atrial fibrillation in patients with CLL.
Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care.
This marks the first time a study identified epidemiological and clinical characteristics of SMM in a general population.
Novel targeted therapies that inhibit specific cellular pathways are promising for patients with CLL.
A team of researchers presented a multi-omics analysis of patients with chronic lymphocytic leukemia.
Advertisement
